Loading...

Endo International

Nasdaq:ENDP
Snowflake Description

Mediocre balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ENDP
Nasdaq
$884M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Endo International has significant price volatility in the past 3 months.
ENDP Share Price and Events
7 Day Returns
-17.3%
NasdaqGS:ENDP
-0.6%
US Pharmaceuticals
0.3%
US Market
1 Year Returns
-57.3%
NasdaqGS:ENDP
6.1%
US Pharmaceuticals
0.7%
US Market
ENDP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Endo International (ENDP) -17.3% -40% -55.4% -57.3% -75.7% -94.3%
US Pharmaceuticals -0.6% 0.2% -3% 6.1% 9% 13.8%
US Market 0.3% 0.4% 0.6% 0.7% 37.2% 37.4%
1 Year Return vs Industry and Market
  • ENDP underperformed the Pharmaceuticals industry which returned 6.1% over the past year.
  • ENDP underperformed the Market in United States of America which returned 0.7% over the past year.
Price Volatility
ENDP
Industry
5yr Volatility vs Market

ENDP Value

 Is Endo International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Endo International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Endo International.

NasdaqGS:ENDP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 17%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ENDP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 12.5%) (928.52%))
4.24
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (2 * 7.14%)
17.01%

Discounted Cash Flow Calculation for NasdaqGS:ENDP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Endo International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ENDP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 17.01%)
2019 803.85 Analyst x2 686.99
2020 990.83 Analyst x3 723.69
2021 1,031.17 Analyst x3 643.67
2022 1,056.17 Analyst x3 563.43
2023 1,070.47 Analyst x3 488.04
2024 1,089.32 Est @ 1.76% 424.44
2025 1,111.67 Est @ 2.05% 370.18
2026 1,136.74 Est @ 2.26% 323.50
2027 1,163.99 Est @ 2.4% 283.10
2028 1,193.06 Est @ 2.5% 247.99
Present value of next 10 years cash flows $4,755.04
NasdaqGS:ENDP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,193.06 × (1 + 2.73%) ÷ (17.01% – 2.73%)
$8,582.86
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,582.86 ÷ (1 + 17.01%)10
$1,784.03
NasdaqGS:ENDP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,755.04 + $1,784.03
$6,539.07
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,539.07 / 226.18
$28.91
NasdaqGS:ENDP Discount to Share Price
Calculation Result
Value per share (USD) From above. $28.91
Current discount Discount to share price of $3.91
= -1 x ($3.91 - $28.91) / $28.91
86.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Endo International is available for.
Intrinsic value
>50%
Share price is $3.91 vs Future cash flow value of $28.91
Current Discount Checks
For Endo International to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Endo International's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Endo International's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Endo International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Endo International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ENDP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.13
NasdaqGS:ENDP Share Price ** NasdaqGS (2019-06-17) in USD $3.91
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.22x
United States of America Market PE Ratio Median Figure of 3,093 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Endo International.

NasdaqGS:ENDP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ENDP Share Price ÷ EPS (both in USD)

= 3.91 ÷ -2.13

-1.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Endo International is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Endo International is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Endo International's expected growth come at a high price?
Raw Data
NasdaqGS:ENDP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
37.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.55x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Endo International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Endo International's assets?
Raw Data
NasdaqGS:ENDP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-2.20
NasdaqGS:ENDP Share Price * NasdaqGS (2019-06-17) in USD $3.91
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.26x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.79x
NasdaqGS:ENDP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ENDP Share Price ÷ Book Value per Share (both in USD)

= 3.91 ÷ -2.20

-1.78x

* Primary Listing of Endo International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Endo International has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.
X
Value checks
We assess Endo International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Endo International has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ENDP Future Performance

 How is Endo International expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Endo International expected to grow at an attractive rate?
  • Endo International's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Endo International's earnings growth is expected to exceed the United States of America market average.
  • Endo International's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ENDP Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ENDP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 37.4%
NasdaqGS:ENDP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts -0.5%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ENDP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ENDP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,828 694 -90 9
2022-12-31 2,824 594 -126 9
2021-12-31 2,911 656 24 12
2020-12-31 2,906 640 5 14
2019-12-31 2,867 144 -68 14
NasdaqGS:ENDP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2,967 128 -477
2018-12-31 2,947 267 -962
2018-09-30 2,929 329 -968
2018-06-30 2,971 434 -921
2018-03-31 3,132 435 -1,565
2017-12-31 3,469 554 -1,233
2017-09-30 3,942 507 -4,294
2017-06-30 4,039 309 -4,386
2017-03-31 4,084 742 -3,300
2016-12-31 4,010 528 -3,224
2016-09-30 3,842 683 553
2016-06-30 3,704 698 -59

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Endo International's earnings are expected to grow significantly at over 20% yearly.
  • Endo International's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ENDP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Endo International Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ENDP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.27 0.27 0.27 1.00
2022-12-31 -0.08 -0.08 -0.08 1.00
2021-12-31 0.79 0.79 0.79 1.00
2020-12-31 1.05 1.20 0.90 2.00
2019-12-31 0.03 0.03 0.03 1.00
NasdaqGS:ENDP Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.13
2018-12-31 -4.29
2018-09-30 -4.33
2018-06-30 -4.12
2018-03-31 -7.01
2017-12-31 -5.52
2017-09-30 -19.25
2017-06-30 -19.67
2017-03-31 -14.81
2016-12-31 -14.48
2016-09-30 2.48
2016-06-30 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Endo International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Endo International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Endo International has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ENDP Past Performance

  How has Endo International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Endo International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Endo International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Endo International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Endo International's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Endo International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Endo International Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ENDP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,966.96 -476.64 633.29 180.57
2018-12-31 2,947.08 -961.77 646.04 185.83
2018-09-30 2,929.33 -967.87 639.24 208.98
2018-06-30 2,970.75 -921.49 611.33 208.94
2018-03-31 3,131.79 -1,565.03 619.13 167.70
2017-12-31 3,468.86 -1,232.71 614.20 172.07
2017-09-30 3,941.73 -4,294.46 666.14 169.73
2017-06-30 4,039.18 -4,386.26 717.00 174.97
2017-03-31 4,084.34 -3,300.45 754.11 184.69
2016-12-31 4,010.27 -3,223.79 770.73 183.37
2016-09-30 3,842.46 553.38 801.99 181.16
2016-06-30 3,703.85 -58.79 759.98 157.60
2016-03-31 3,518.13 -539.37 721.40 125.99
2015-12-31 3,268.72 -300.12 703.70 102.20
2015-09-30 2,857.90 -724.71 592.42 88.75
2015-06-30 2,766.29 127.86 649.44 88.24
2015-03-31 2,623.97 260.00 615.90 99.66
2014-12-31 2,380.68 58.47 567.99 112.71
2014-09-30 2,302.75 -643.01 609.20 115.79
2014-06-30 2,309.96 -637.15 598.82 131.66
2014-03-31 2,429.26 -649.86 722.17 134.65
2013-12-31 2,124.68 188.70 574.31 97.47
2013-09-30 2,621.39 -628.43 828.71 144.92
2013-06-30 2,710.56 -629.41 847.80 157.19
2013-03-31 2,783.60 -648.58 837.12 169.22
2012-12-31 2,815.74 -746.32 864.34 219.14
2012-09-30 3,029.71 12.52 910.22 238.50
2012-06-30 3,038.31 -0.64 948.12 233.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Endo International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • Endo International used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Endo International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Endo International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Endo International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ENDP Health

 How is Endo International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Endo International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Endo International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Endo International's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Endo International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Endo International has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Endo International Company Filings, last reported 2 months ago.

NasdaqGS:ENDP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -494.45 8,211.57 981.74
2018-12-31 -498.28 8,292.54 1,149.11
2018-09-30 -219.46 8,262.76 1,118.89
2018-06-30 -62.08 8,267.21 1,098.79
2018-03-31 -7.09 8,271.69 980.41
2017-12-31 484.88 8,276.24 986.61
2017-09-30 764.98 8,280.81 738.39
2017-06-30 809.11 8,285.44 616.53
2017-03-31 2,188.05 8,250.17 617.59
2016-12-31 2,701.59 8,272.50 517.25
2016-09-30 6,050.86 8,294.87 561.58
2016-06-30 6,261.54 8,317.34 667.86
2016-03-31 5,924.15 8,564.77 222.01
2015-12-31 5,967.98 8,580.36 272.38
2015-09-30 6,396.05 8,979.33 836.88
2015-06-30 6,151.94 5,429.65 2,530.63
2015-03-31 4,139.72 5,547.16 378.56
2014-12-31 2,408.21 4,256.56 406.51
2014-09-30 2,530.19 4,372.54 713.87
2014-06-30 2,844.62 4,415.53 1,473.52
2014-03-31 3,037.36 3,897.89 1,115.56
2013-12-31 585.22 3,738.77 526.60
2013-09-30 1,337.36 3,056.32 594.09
2013-06-30 1,251.55 3,066.44 505.61
2013-03-31 1,171.74 3,078.03 340.52
2012-12-31 1,133.21 3,167.19 529.69
2012-09-30 1,930.52 3,194.47 256.92
2012-06-30 1,952.62 3,290.11 391.95
  • Endo International has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Endo International's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Endo International has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Endo International has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 19.4% per year.
X
Financial health checks
We assess Endo International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Endo International has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ENDP Dividends

 What is Endo International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Endo International dividends. Estimated to be 0% next year.
If you bought $2,000 of Endo International shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Endo International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Endo International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ENDP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ENDP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Endo International has not reported any payouts.
  • Unable to verify if Endo International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Endo International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Endo International has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Endo International's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Endo International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Endo International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Endo International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ENDP Management

 What is the CEO of Endo International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Campanelli
COMPENSATION $19,970,703
AGE 56
TENURE AS CEO 2.8 years
CEO Bio

Mr. Paul V. Campanelli has been the Chief Executive Officer, President, and Executive Director at Endo International plc since September 23, 2016. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc. from 2011 to 2012. At Par Pharmaceutical Inc., Mr. Campanelli had also served as Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by its board of directors. He serves as a Director at Par Pharmaceutical Holdings, Inc. He also served on the board of directors of Sky Growth Holdings Corporation from 2012 until 2015. Mr. Campanelli joined Par Pharmaceutical Companies Inc. in 2001. Prior to joining Par Pharmaceutical Companies Inc., Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992 to 2001. Mr. Campanelli earned his Bachelor of Science degree from Springfield College.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Endo International management team in years:

2.5
Average Tenure
49
Average Age
  • The tenure for the Endo International management team is about average.
Management Team

Paul Campanelli

TITLE
President
COMPENSATION
$20M
AGE
56
TENURE
2.8 yrs

Blaise Coleman

TITLE
Executive VP & CFO
COMPENSATION
$3M
AGE
44
TENURE
2.5 yrs

Terry Coughlin

TITLE
Executive VP & COO
COMPENSATION
$3M
AGE
52
TENURE
2.6 yrs

Matt Maletta

TITLE
Executive VP & Chief Legal Officer
COMPENSATION
$3M
AGE
46
TENURE
4.1 yrs

Tony Pera

TITLE
President of Par Pharmaceutical
COMPENSATION
$2M
AGE
61
TENURE
2.6 yrs

Carrie Nichol

TITLE
Senior VP
AGE
38
TENURE
1.2 yrs

Laure Park

TITLE
Senior Vice President of Investor Relations & Corporate Affairs
TENURE
0.8 yrs

Susan Williamson

TITLE
Senior VP & Chief Compliance Officer
TENURE
1.2 yrs

Mark Bradley

TITLE
Senior VP of Corporate Development & Treasurer
TENURE
2.5 yrs

Larry Cunningham

TITLE
Executive Vice President of Human Resources
Board of Directors Tenure

Average tenure and age of the Endo International board of directors in years:

5.3
Average Tenure
69
Average Age
  • The tenure for the Endo International board of directors is about average.
Board of Directors

Roger Kimmel

TITLE
Chairman of the Board
COMPENSATION
$450K
AGE
72
TENURE
5.3 yrs

Paul Campanelli

TITLE
President
COMPENSATION
$20M
AGE
56
TENURE
2.8 yrs

Michael Hyatt

TITLE
Independent Director
COMPENSATION
$315K
AGE
72
TENURE
5.3 yrs

Bill Montague

TITLE
Independent Director
COMPENSATION
$320K
AGE
71
TENURE
5.3 yrs

Nancy Hutson

TITLE
Independent Director
COMPENSATION
$320K
AGE
69
TENURE
5.3 yrs

Shane Cooke

TITLE
Independent Director
COMPENSATION
$325K
AGE
56
TENURE
4.9 yrs

Sharad Mansukani

TITLE
Senior Independent Director
COMPENSATION
$360K
AGE
48
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
10. Dec 18 Sell William Montague Individual 10. Dec 18 10. Dec 18 -10,000 $11.41 $-114,100
X
Management checks
We assess Endo International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Endo International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ENDP News

Simply Wall St News

Endo International plc (NASDAQ:ENDP): When Will It Breakeven?

Many investors are wondering the rate at which ENDP will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for ENDP, its year of breakeven and its implied growth rate. … See our latest analysis for Endo International ENDP is bordering on breakeven, according to the 14 Pharmaceuticals analysts. … In order to meet this breakeven date, I calculated the rate at which ENDP must grow year-on-year.

Simply Wall St -

Easy Come, Easy Go: How Endo International (NASDAQ:ENDP) Shareholders Got Unlucky And Saw 91% Of Their Cash Evaporate

View our latest analysis for Endo International Endo International isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … NasdaqGS:ENDP Income Statement, May 14th 2019 Endo International is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. … A Different Perspective It's good to see that Endo International has rewarded shareholders with a total shareholder return of 4.7% in the last twelve months.

Simply Wall St -

How Much Are Endo International plc (NASDAQ:ENDP) Insiders Taking Off The Table?

So we'll take a look at whether insiders have been buying or selling shares in Endo International plc (NASDAQ:ENDP). … Endo International Insider Transactions Over The Last Year. … Over the last year, we can see that the biggest insider sale was by the Independent Director, William Montague, for US$114k worth of shares, at about US$11.41 per share.

Simply Wall St -

Does Endo International plc (NASDAQ:ENDP) Have A High Beta?

Volatility is considered to be a measure of risk in modern finance theory. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Endo International plc (NASDAQ:ENDP): When Will It Breakeven?

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. … The US$2.5b market-cap company announced a latest loss of -US$961.8m on 31 December 2018 for its most recent financial year result. … In this article, I will touch on the expectations for ENDP’s growth and when analysts expect the company to become profitable

Simply Wall St -

Investors Are Undervaluing Endo International plc (NASDAQ:ENDP) By 39.38%

How far off is Endo International plc (NASDAQ:ENDP) from its intrinsic value? … by taking the foreast future cash flows of the company and discounting them back to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Was Endo International plc's (NASDAQ:ENDP) Earnings Growth Better Than The Industry's?

Today I will assess ENDP's recent performance announced on 31 March 2018 and evaluate these figures to its longer term trend and industry movements. … How ENDP fared against its long-term earnings performance and its industry. … ENDP is loss-making, with the most recent trailing twelve-month earnings of -US$1.57b (from 31 March 2018), which compared to last year has become

Simply Wall St -

Why I Sold Endo International plc (NASDAQ:ENDP)

Whether a company has a good future, in terms of its business operation and financial health, is an important question to address. … One reason I do like ENDP as a business is its low level of fixed assets on its balance sheet (7.87% of total assets). … A good company is reflected in its financials, and for ENDP, the financials don't look good.

Simply Wall St -

When Will Endo International plc (NASDAQ:ENDP) Turn A Profit?

Check out our latest analysis for Endo International Expectation from analysts is ENDP is on the verge of breakeven. … It turns out an average annual growth rate of 46.78% is expected, which signals high confidence from analysts. … If this rate turns out to be too aggressive, ENDP may become profitable much later than analysts predict.

Simply Wall St -

When Should You Buy Endo International plc (NASDAQ:ENDP)?

Great news for investors – Endo International is still trading at a fairly cheap price. … Endo International’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price.

Simply Wall St -

ENDP Company Info

Description

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company’s U.S. Branded - Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. The company’s International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women’s health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland.

Details
Name: Endo International plc
ENDP
Exchange: NasdaqGS
Founded: 1920
$884,370,278
226,181,657
Website: http://www.endo.com
Address: Endo International plc
Minerva House,
First Floor,
Dublin,
Co. Dublin, 4,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ENDP Common Stock Nasdaq Global Select US USD 18. Jul 2000
DB EO7 Common Stock Deutsche Boerse AG DE EUR 18. Jul 2000
LSE 0Y5F Common Stock London Stock Exchange GB USD 18. Jul 2000
BMV ENDP N Common Stock Bolsa Mexicana de Valores MX MXN 18. Jul 2000
Number of employees
Current staff
Staff numbers
2,910
Endo International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 23:37
End of day share price update: 2019/06/17 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.